Start-up
Memo Therapeutics AG
About Memo Therapeutics
Memo Therapeutics AG (”MTx”) is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTx’ lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection. AntiBKV has successfully completed Phase I with no safety concerns, with Phase II (POC) data expected in H1 2025. MTx’ pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus (“CMV”), undisclosed immuno-oncology targets as well as a partnership with Ono Pharmaceutical.
- Founding: 2012
- Focus : Manufacturer
- Industry : Biotechnology
Product portfolio of Memo Therapeutics
News about Memo Therapeutics
Here you will find Memo Therapeutics AG
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
